HONG-YUAN HSUMEI-HWEI CHANG2019-12-252019-12-2520190022-3476https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053724527&doi=10.1016%2fj.jpeds.2018.08.017&partnerID=40&md5=5efa1de518448dc66322c7ffcbf21ba0https://scholars.lib.ntu.edu.tw/handle/123456789/438985English[SDGs]SDG3antivirus agent; hepatitis B vaccine; antivirus agent; hepatitis B vaccine; Article; body fluid; cost effectiveness analysis; disease elimination; disease eradication; endemic disease; global disease burden; hepatitis B; human; immunological tolerance; immunoprophylaxis; liver cell; liver cell carcinoma; macrophage function; morbidity; priority journal; sexual intercourse; T lymphocyte; vaccination; vertical transmission; virus hepatitis; adult; child; female; global health; hepatitis B; immunology; infant; male; mass screening; newborn; pregnancy; prevention and control; preventive health service; procedures; Adult; Antiviral Agents; Child; Disease Eradication; Female; Global Health; Hepatitis B; Hepatitis B Vaccines; Humans; Immunization Programs; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Mass Screening; Pregnancyjournal article10.1016/j.jpeds.2018.08.017302449842-s2.0-85053724527